Characterizing relapse prevention in bipolar disorder with adjunctive ziprasidone: clinical and methodological...

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Trials

Background:

• Ziprasidone adjunctive to lithium or valproate reduces relapse risk in bipolar disorder compared to monotherapy.
• Bipolar disorder management often involves mood stabilizers like lithium and valproate.

Purpose of the Study:

• To analyze post hoc data on ziprasidone's effectiveness in preventing bipolar disorder relapse.
• To investigate relapse outcomes based on ziprasidone dosage, relapse types, timing, and discontinuation rates.

Main Methods:

• A 6-month, double-blind, placebo-controlled trial involving patients with bipolar I disorder experiencing manic or mixed episodes.
• Patients received ziprasidone (80-160mg/day) as an adjunct to lithium or valproate, or lithium/valproate alone.
• Post hoc analyses focused on relapse and discontinuation rates across different ziprasidone doses.

Main Results:

• Ziprasidone 120mg/day significantly reduced time to relapse and all-cause discontinuation compared to placebo (p=0.004 and p=0.001).
• No significant differences in relapse or discontinuation were observed for ziprasidone 80mg/day or 160mg/day versus placebo.
• Most relapses occurred early (before week 8) and were predominantly depressive in nature.

Conclusions:

• Ziprasidone (80-160mg/day) is effective in preventing bipolar disorder relapses when used adjunctively.
• The 120mg/day dosage of ziprasidone demonstrated the highest relapse prevention rate in this analysis.
• The primary study was not powered to compare relapse rates between specific dose groups.